A statistically significant 40% improvement of both overall survival and progression-free survival in a large population of patients, identified by a pre-specified analysis on the prior treatment-free interval, and who presented a very dismal prognosis was reported by MolMed S.p.A. this weekend, at the 50th ASCO annual meeting.
Source: www.topix.com Via newsmixx: home News